Company Announcement / Press release Archives

New number of shares and votes in Xspray Pharma after new share issue April 2026

Xspray Pharma AB (Nasdaq Stockholm: XSPRAY) today announces that the number of shares and votes in Xspray Pharma AB has changed. New shares have been issued as a result of the rights issue and over-allotment issue announced on March 24, 2026. On March 26, 2026, the Board of Directors also decided to increase the over-allotment […]

Interim Report First Quarter 2026

January–March 2026, Group Net sales amounted to SEK 0 thousand (0) Earnings before tax amounted to SEK -35,380 thousand (-42,321) Earnings per share before dilution amounted to SEK -0.85 (-1.14) Cash flow from operating activities amounted to SEK -30,676 thousand (-66,329) Cash flow from investing activities amounted to SEK -1,067 thousand (-14,701) Amounts in parentheses […]

Xspray’s rights issue oversubscribed – over-allotment issue fully utilized

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL OR DEMAND ADDITIONAL […]

FDA accepts trade name Nilopki® for Xspray’s drug candidate XS003 (nilotinib)

The US Food and Drug Administration (FDA) has accepted Nilopki® as the proprietary name for Xspray Pharma's drug candidate XS003 (nilotinib). Nilopki is an improved, amorphous formulation of nilotinib (Tasigna®) for the treatment of chronic myeloid leukemia (CML), developed on Xspray's proprietary HyNap™ platform. Upon market approval, Xspray plans to launch Nilopki® in the US […]

Notice of annual general meeting of Xspray Pharma AB (publ)

The shareholders of Xspray Pharma AB (publ), Reg. No. 556649-3671, (”Xspray Pharma”) are summoned to the annual general meeting on Tuesday 12 May 2026 at 10.00 CEST at Advokatfirman Vinge’s office on Smålandsgatan 20 in Stockholm. Registration starts at 9.30 CEST. The shareholders may exercise their voting rights at the annual general meeting by attending […]

Xspray publishes disclosure document regarding rights issue

Xspray receives additional subscription undertakings; rights issue now covered to 110% and over-allotment issue increased

Xspray Pharma publishes its Annual Report 2025

Xspray Pharma AB (Nasdaq Stockholm: XSPRAY) today publishes its Annual Report for the financial year 2025. An extract from the CEO-letter from Per Andersson, CEO of Xspray Pharma:“In 2025, Xspray took several decisive steps on our journey to becoming a commercial pharmaceutical company. While we cannot yet determine the outcome of the ongoing regulatory processes, […]

Xspray resolves on a rights issue of approximately SEK 83 million with an over-allotment issue

Xspray Pharma: FDA accepts resubmitted application for market approval of Dasynoc® – PDUFA date August 25, 2026

The U.S. Food and Drug Administration (FDA) has accepted Xspray Pharma's resubmitted New Drug Application (NDA) for Dasynoc® for review under the 505(b)(2) procedure. The FDA has set a PDUFA date of August 25, 2026, which is the date when the agency is expected to announce a decision on the application. Xspray thus plans to […]